This is Thomas Sullivan - Policy & Medicine Writing Staff's Typepad Profile.
Join Typepad and start following Thomas Sullivan - Policy & Medicine Writing Staff's activity
Join Now!
Already a member? Sign In
Thomas Sullivan - Policy & Medicine Writing Staff
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
Earlier this week, the Food and Drug Administration (FDA) held a public hearing entitled “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access,” to address the agency’s plan to increase competition on the drug market while fostering innovation. A... Continue reading
Posted 2 days ago at Policy and Medicine
Image
Seven states and the District of Columbia currently have regulations that limit or ban industry gifts to physicians, and it seems as though others are following suit. The California state Senate passed SB 790 in May 2017, a bill restricting... Continue reading
Posted 2 days ago at Policy and Medicine
Image
In January 2015, HHS set the target of funneling 50% of Medicare payments through alternative payment models and tying 90% of fee-for-service payments to quality or value by the end of 2018. MACRA is part of that shift by changing... Continue reading
Posted 3 days ago at Policy and Medicine
Image
On Thursday, July 13, 2017, United States Attorney General Jeff Sessions and Department of Health and Human Services (HHS) Secretary Tom Price, M.D., announced the largest ever health care fraud enforcement action by the Medicare Fraud Strike Force. The action... Continue reading
Posted 4 days ago at Policy and Medicine
Image
Measuring the effectiveness of compliance programs is no easy task since governing agencies have not published a template that will work in all cases; compliance measurements are unique to each company’s size, operations, resources and risks factors. Although there is... Continue reading
Posted 4 days ago at Policy and Medicine
Image
On Wednesday, July 12, 2017, the United States House of Representatives passed a bill via voice vote to reauthorize the prescription drug, generic drug, medical device and biosimilar user fee programs through 2022. The current user fee programs expire September... Continue reading
Posted 5 days ago at Policy and Medicine
Image
The Accreditation Council for Continuing Medical Education (ACCME®) recently released the ACCME Data Report: Growth and Evolution in Continuing Medical Education — 2016. The 2016 report includes data from a community of over 1,800 accredited continuing medical education (CME) providers... Continue reading
Posted 6 days ago at Policy and Medicine
Image
At the 14th Annual CBI Pharmaceutical Compliance Congress held in April 2017, almost half the attendees were from small to mid-sized companies that generate $3 billion or less in annual revenue. At the same time, the compliance burdens for all... Continue reading
Posted 6 days ago at Policy and Medicine
Image
In early June 2017, the Pharmaceutical Research and Manufacturers of America (PhRMA) – in partnership with the American Cancer Society Cancer Action Network (ACS CAN) – released a report that found there are over 240 immuno-oncology medicines and vaccines currently... Continue reading
Posted Jul 14, 2017 at Policy and Medicine
Image
Already in 2017, the FDA has approved a number of new drugs, which Regulatory Focus points out as a trend away from the low number of new drugs approved in 2016. They caution, however, it is unlikely to match the... Continue reading
Posted Jul 13, 2017 at Policy and Medicine
Image
We continue to follow the President’s budgets with potential cuts to the NIH and possible legislation to address drug prices. With that in mind, HHS Secretary Tom Price’s testimony in front of a House appropriations subcommittee is particularly relevant. The... Continue reading
Posted Jul 12, 2017 at Policy and Medicine
Image
Many highly criticize President Trump’s fiscal year 2018 budget, for a variety of reasons. Many are opining that the projected spending cuts across the government would be dramatic, including cuts to “Obamacare” outlays by $1.25 trillion, through the American Health... Continue reading
Posted Jul 11, 2017 at Policy and Medicine
Image
In November 2017, the state of Ohio will have a proposed statute included on the ballot for voters to approve, known as the “Ohio Drug Price Relief Act.” The proposal was written by California activist Michael Weinstein, the same author... Continue reading
Posted Jul 10, 2017 at Policy and Medicine
Image
On June 16, 2017, the President’s Commission on Combating Drug Addiction and Opioid Crisis held its first meeting to discuss ways in which to curb the current opioid epidemic through best practices of prevention and treatment. During the meeting, Commission... Continue reading
Posted Jul 7, 2017 at Policy and Medicine
Image
A topic of much discussion, but few solutions, has been healthcare in America. President Donald Trump was supposedly elected, in part, because of his promises to “Repeal and Replace” the Affordable Care Act, aka “Obamacare.” Many politicians and reporters were... Continue reading
Posted Jul 6, 2017 at Policy and Medicine
Image
The Medicare Payment Advisory Commission (MedPAC) released its annual Report to the Congress on Medicare and the Health Care Delivery System (the “Report”) on June 15, 2017. While the report makes many suggestions, one important one is the discussion of... Continue reading
Posted Jul 5, 2017 at Policy and Medicine
Image
2016 Open Payments Data was released on Friday, June 30, 2017. In 2016, the total dollar amount of payments totaled $8.18 billion. The total amount of general payments made amounted to $2.80 billion; the total amount of research payments amounted... Continue reading
Posted Jul 3, 2017 at Policy and Medicine
Image
According to a RAND study in Health Affairs, MACRA will slow the rate of growth for the program's spending on physician services, saving anywhere from $35 billion to $106 billion over 15 years. Over this time, the relative drop in... Continue reading
Posted Jun 30, 2017 at Policy and Medicine
Image
The 21st Century Cures Act (“Act”), which provides substantial funding for medical research, seeks to alleviate the regulatory process for developmental and experimental treatments and to implement reform measures on mental health care. This article explores whether the long-term the... Continue reading
Posted Jun 30, 2017 at Policy and Medicine
Image
The City of Chicago recently released a draft of the disclosure log pharmaceutical representatives will be expected to use to keep track of the interactions they have with Chicago physicians. The form requires pharmaceutical representatives to log the following information... Continue reading
Posted Jun 29, 2017 at Policy and Medicine
Image
Lawmakers across America have started to take a variety of matters into their own hands, the most recent of which is Maintenance of Certification (MOC) licensure requirements. This trend started late last year when Oklahoma became the first state to... Continue reading
Posted Jun 28, 2017 at Policy and Medicine
Image
Allergan has been hit with hefty fines over the past several months. This article outlines Allergan's alleged wrongdoing, and the settlement amount agreed to by the government and Allergan. The Life Science industry is no stranger to sales representatives as... Continue reading
Posted Jun 28, 2017 at Policy and Medicine
Image
The Maine Legislature recently passed LD 911, An Act to Prohibit Certain Gifts to Health Care Practitioners, through the unanimous consent calendar. This bill amends the Maine Pharmacy Act to prohibit a person engaged in the manufacture of prescription drugs... Continue reading
Posted Jun 27, 2017 at Policy and Medicine
Image
On Tuesday, June 27, 2017, California Senate Bill 790 will be heard in the Assembly Committee on Health, with limited testimony allowed per side. We have previously written about the bill, noting that the bill passed the California Senate back... Continue reading
Posted Jun 26, 2017 at Policy and Medicine
Image
In constructively bringing an end to a False Claims Act (“FCA”) whistleblower suit alleging Genentech, Inc. (“Genentech”) of defrauding Medicare by way of concealing substantive health care analytics data involving purported side effects of the company’s cancer drug Avastin, the... Continue reading
Posted Jun 26, 2017 at Policy and Medicine